fbpx
Home Tags Loxo Oncology

Tag: Loxo Oncology

Quintet of new leasing deals at Stamford Plaza

Two of the tenants are relocating from New York City, another is relocating within Stamford, and the others are significantly expanding their footprints within Stamford Plaza.

Eli Lilly to buy Loxo Oncology for $8 billion

Loxo Oncology CEO Josh Bilinker praised Eli Lilly for recognizing "our contributions to the field of precision medicine."

Stamford’s Loxo Oncology receives FDA approval on cancer drug

"The approval of Vitrakvi is a testament to the relentless prioritization of biology in the drug development process," said Josh Bilenker, CEO of Loxo Oncology.

Stamford’s Loxo Oncology receives FDA ‘breakthrough’ designation for cancer treatment drug

The medication is designed for certain thyroid cancer patients.

Loxo Oncology teams with Illumina on tumor profiling project

Stamford-based Loxo Oncology has entered into a global strategic partnership with San Diego-based Illumina Inc. to commercially develop a multi-gene panel for broad tumor profiling.

Loxo Oncology completes rolling submission of new drug application for larotrectinib

Stamford-based Loxo Oncology Inc has announced its completion of the rolling submission of a new drug application to the U.S. Food and Drug Administration for the TRK inhibitor treatment larotrectinib.

Stamford’s Loxo Oncology in multimillion-dollar cancer drug partnership with Bayer

Loxo Oncology will receive an upfront payment of $400 million and will be eligible for $450 million in milestone payments upon regulatory approvals.

Stamford’s Loxo Oncology looks to raise $227M for cancer treatment via...

Loxo Oncology Inc. expects to raise approximately $226.8 million next week by offering 3,150,000 shares of common stock at a public offering price of $72 per share.